ArticleFrontiers in cardiovascular medicine2025
The level of human epididymis protein 4 is associated with poor prognosis in patients with ejection fraction preserved heart failure.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The prognostic value of human epididymis protein 4 (HE4) in patients with heart failure with preserved ejection fraction (HFpEF) is unknown. Methods: Patients diagnosed with HFpEF in the Department of Cardiovascular Medicine of Hunan Provincial People's Hospital from January 2021 to August 2022 were prospectively enrolled in the study. Serum levels of HE4 were measured using a chemiluminescence microparticle immunoassay. Endpoint events included readmission for heart failure and cardiovascular death. Results: A total of 170 patients with HFpEF were included in the study; among them, 86 (50.6%) were male, with a mean age of 68.9 ± 0.8 years. A total of 71 patients experienced endpoint events, including 67 patients with rehospitalizations for heart failure and 4 patients with cardiovascular deaths, with an average follow-up of 18.0 ± 0.8 months. Multivariate Cox regression analysis revealed that HE4 was an independent predictor of endpoint events (HR = 1.009, 95% CI 1.002-1.015, Conclusion: HE4 is an independent predictor of heart failure rehospitalization and cardiovascular death in patients with HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.